{"pageContent": "Background: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial showed the survival benefit for prostate radiotherapy in newly diagnosed prostate cancer patients with a low metastatic burden. The result raises the next question whether additional radiotherapy to metastatic sites could improve the survival in those with a low metastatic burden.", "metaData": {"source": "An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/11085533/"}}